Repligen

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Repligen (RGEN) reports strong 2022 performance, eyes growth amid challenges

Repligen anticipates a challenging yet optimistic year in 2023, with revenue guidance of $760-800 million and adjusted EPS of $2.61-2.69 per fully diluted share. The company remains focused on organic growth, innovation, and strategic acquisitions to navigate industry headwinds.

Repligen reports Q1 revenue growth, eyes China rebound and new products

Repligen's Q1 2023 performance saw revenue growth but overall revenues declined due to reduced COVID-related demand.
Despite challenges in China and revised guidance, strategic investments and confidence in future growth opportunities remain strong.
The company is focused on new product launches, pricing resilience, and addressing challenges to drive growth and margin improvement.

Repligen faces revenue decline and margin pressure, eyes growth strategies

Repligen faces challenges in revenue decline and margin compression but is focusing on cost control and new product launches for growth.
Diversified revenue streams and positive developments in orders and integration provide a foundation for future opportunities.
Market dynamics and pharma spend challenges pose uncertainties, but the company remains optimistic about growth prospects.
Visibility improvements, margin recovery expectations, and pricing strategies are key focus areas for future profitability.

Repligen sees recovery in Q3 amidst industry challenges and restructuring

Repligen's Q3 2023 showed signs of recovery amidst industry challenges, with a focus on cost optimization and new product launches. The company incurred restructuring charges to streamline operations and expects improved margins in 2024. Despite revenue declines, opportunities lie in the gene therapy segment and future recovery in China.

Repligen reports Q4 revenue decline but eyes growth in China

Repligen's Q4 2023 showed mixed results with revenue decline but sequential growth. The company is focusing on profitability improvements in 2024 and anticipates growth driven by new modalities and market recovery. Challenges in revenue performance are being addressed, with a strategic focus on key account management and cost containment.

Repligen reports mixed Q1 results, focuses on innovation and growth

Repligen's Q1 2024 performance showed mixed results with revenue declines but positive growth in key segments. The company maintains its focus on innovation, cost control, and strategic expansion while navigating challenges in profitability. Opportunities lie in market improvements and growth potential in new modalities.

Repligen reports strong Q2 performance, eyes robust growth ahead

Repligen's Q2 2024 earnings call showcased strong performance in pharma and consumables, despite challenges from China and foreign exchange. The company anticipates a return to robust revenue growth in the second half of the year and is optimistic about future growth prospects.

Repligen (RGEN) reports robust Q3 results and eyes 2025 growth

Repligen is on track to meet 2024 revenue guidance, entering 2025 in a strong position.
Exciting product launches planned for 2025 across all business units.
Strong start to Q4 with confidence in meeting financial targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “Making an Impact”, the report highlights the company's measurable progress across multiple environmental, social and governance (ESG) initiatives since its inaugural 2020 Sustainability Report, “Committed to Making a Difference”. Supporting the 2022 Sustainability Report is a Reporting Indexes document containing disclosures against the following frameworks: Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs), and Task Force on Climate-Related Disclosures (TCFD). See the Sustainability section of Repligen's website for more information.

UPDATE – Repligen Announces Publication of the Company's 2022 Sustainability Report

WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “Making an Impact”, the report highlights the company's measurable progress across multiple environmental, social and governance (ESG) initiatives since its inaugural 2020 Sustainability Report, “Committed to Making a Difference”. Supporting the 2022 Sustainability Report is a Reporting Indexes document containing disclosures against the following frameworks: Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs), and Task Force on Climate-Related Disclosures (TCFD).

Repligen Announces Publication of the Company's 2022 Sustainability Report

WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® SC, the industry's first holder-free, self-contained Tangential Flow Filtration (TFF) device.

Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device

Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023.

Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat

Repligen Corporation (NASDAQ:RGEN ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Sondra Newman – Head of Investor Relations Tony Hunt – Chief Executive Officer Jason Garland – Chief Financial Officer Conference Call Participants Jacob Johnson – Stephens Conor McNamara – RBC Capital Markets Dan Arias – Stifel Puneet Souda – Leerink Partners Matt Larew – William Blair Matt Hewitt – Craig-Hallum Capital Group Tim Daley – Wells Fargo Rachel Vatnsdal – J.P. Morgan Dan Leonard – UBS Justin Bowers – Deutsche Bank Brandon Couillard – Jefferies Operator Good day, ladies and gentlemen, and welcome to Repligen's 2023 Third Quarter Earnings Conference Call.

Repligen Corporation (RGEN) Q3 2023 Earnings Call Transcript

Repligen (RGEN) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.77 per share a year ago.

Repligen (RGEN) Tops Q3 Earnings and Revenue Estimates

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2023, covering the three- and nine-month fiscal periods ended September 30, 2023.

Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline

Avantor Inc.

Catalent

Danaher

DexCom

Inspire Medical Systems Inc

Coca-Cola

Eli Lilly

Novo Nordisk

PepsiCo

Insulet

Thermo Fisher Scientific

Walmart

Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same period.

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

Webcast and Conference Call to Be Held Tuesday, October 31, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 31, 2023, at 8:30 a.m. ET

Repligen to Report Third Quarter 2023 Financial Results

WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately. Mr. Loeillot served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. In his most recent role at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. Prior to Cytiva, he worked for a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing. Mr. Loeillot joins Repligen from his most recent role as Chief Executive Officer (CEO) of Ascensus Specialties, a manufacturer of specialty chemicals for use in the life sciences and pharmaceutical markets.

Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology applications.

Repligen (RGEN) to Acquire Fluid Management Company Metenova

WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Metenova AB (Metenova) of Mölndal, Sweden. Metenova is projected to generate revenues of $24 million to $25 million for fiscal year 2023, led by the success of its magnetic mixing and drive train technologies that are widely used by global biopharmaceutical companies and contract development and manufacturing organizations (CDMOs). The company recently entered the single-use mixing market with the launch of its MixOne platform, leveraging the success of its existing stainless steel (repeat-use) product line.

Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Why Is Repligen (RGEN) Up 2.9% Since Last Earnings Report?

WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF upstream intensification technology into Sartorius' Biostat STR® bioreactor, simplifying intensified seed train and N perfusion implementation for biopharmaceutical manufacturers. The Biostat STR® now contains a fully compatible embedded XCell® ATF hardware and software module offering predefined advanced control recipes with integrated Process Analytical Technology (PAT). This system gives users a streamlined way to control cell growth and improve cell retention in perfusion processes without using a separate cell retention control tower.

Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification

Repligen's (RGEN) second-quarter earnings and revenues beat their respective Zacks Consensus Estimate. Chromatography and process analytics businesses are the key growth drivers in the quarter.

Repligen (RGEN) Beats on Q2 Earnings, Lowers '23 Guidance

Repligen Corporation (NASDAQ:RGEN ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Jacob Johnson - Stephens Dan Arias - Stifel Matt Larew - William Blair Rachel Vatnsdal - J.P. Morgan Paul Knight - KeyBanc Capital Markets Conor McNamara - RBC Capital Markets Matt Hewitt - Craig Hallum Lisa Garcia - UBS Timothy Daley - Wells Fargo Brandon Couillard - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Repligen Corporation Second Quarter of 2023 Earnings Conference Call.

Repligen Corporation (RGEN) Q2 2023 Earnings Call Transcript

Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.91 per share a year ago.

Repligen (RGEN) Q2 Earnings Surpass Estimates

– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year

Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

Earnings Preview: Repligen (RGEN) Q2 Earnings Expected to Decline

Exelixis

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Repligen (RGEN). But which of these two stocks presents investors with the better value opportunity right now?

EXEL or RGEN: Which Is the Better Value Stock Right Now?

Webcast and Conference Call to Be Held Wednesday, August 2, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, August 2, 2023, at 8:30 a.m. ET

Repligen to Report Second Quarter 2023 Financial Results

Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use products for biopharma manufacturing. The company is expected to grow further due to the increasing adoption of single-use systems in biopharma manufacturing, the development of new vaccines and therapeutics, and strategic acquisitions. Despite headwinds such as a reduction in COVID-related demand and weak sales in China, Repligen anticipates a resurgence in growth exceeding 20% in FY24.

Repligen: The Hidden Gem In Single-Use Solutions For Biopharma Manufacturing

Repligen Corporation is facing tougher comparables with the pandemic-related revenue contribution vanishing. This is expected, but the softer organic growth in the base business is disappointing. With valuations still being demanding, I am fearful of Repligen Corporation's high valuation given the interest rate environment and softer operating performance.

News for Repligen Stock (RGEN)